Abstract
PPD01.07 Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have